Showing results (61-70 of 112) with videos related to

Sort By:
Pageof 12
Ebiomedicine|May 29, 2021
CT radiomics-based machine learning classification of atypical cartilaginous tumours and appendicular chondrosarcomasSalvatore Gitto, Renato Cuocolo, Alessio Annovazzi, et al.
Journal of Surgical Oncology|February 22, 2023
A prognostic score from a multicentric retrospective analysis of patients affected by sarcoma with metachronous lung metastases undergoing metastasectomyFilippo Tommaso Gallina, Enrico Melis, Luca Bertolaccini, et al.
Journal of Clinical Medicine|November 28, 2019
Impact of Antiretroviral Therapy on the Risk of Recurrence in HIV-1 Infected Patients with Kaposi Sarcoma: A Multicenter Cohort ExperienceManuela Colafigli, Arturo Ciccullo, Alberto Borghetti, et al.
The Lancet. Oncology|December 16, 2014
Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trialGiovanni Grignani, Emanuela Palmerini, Virginia Ferraresi, et al.
Frontiers in Oncology|December 19, 2022
3D vs. 2D MRI radiomics in skeletal Ewing sarcoma: Feature reproducibility and preliminary machine learning analysis on neoadjuvant chemotherapy response predictionSalvatore Gitto, Valentina D A Corino, Alessio Annovazzi, et al.
Journal of Translational Medicine|August 13, 2025
Development of an innovative duplex digital PCR assay for circulating MiRNA ratio quantification in metastatic melanomaAlex De Gregorio, Andrea Sacconi, Chiara Mandoj, et al.
Cancers|July 3, 2020
Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with CrossoverCeleste Lebbé, Caroline Dutriaux, Thierry Lesimple, et al.
The Lancet. Oncology|March 25, 2018
Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trialHans Gelderblom, Claire Cropet, Christine Chevreau, et al.
Journal of Experimental & Clinical Cancer Research : CR|April 20, 2022
SEMA6A/RhoA/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF/MEK inhibition in BRAF-mutant melanomaRossella Loria, Valentina Laquintana, Stefano Scalera, et al.
Journal of Neuro-Oncology|February 18, 2014
Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastasesPaola Queirolo, Francesco Spagnolo, Paolo Antonio Ascierto, et al.
Pageof 12